secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001558370-24-009225
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics doses first patient in Phase 1 trial of oral WEE1 inhibitor APR-1051
--------------------------------------------------------------------------------

- First patient dosed in ACESOT-1051 Phase 1 trial of oral WEE1 inhibitor APR-1051 as monotherapy in advanced solid tumors.
- APR-1051 is a potent, highly selective WEE1 inhibitor designed to limit off-target PLK inhibition and improve PK profile.
- Trial targets tumors with CCNE1/2 amplification, FBXW7/PPP2R1A mutations, KRAS-G12/TP53 co-mutated CRC, or uterine serous carcinoma.
- Dose escalation (up to 39 patients) and dose optimization (up to 40 patients) to determine RP2D; first site at NEXT Oncology (San Antonio).
- Company expects clinical update by year-end 2024 and preliminary efficacy data in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000155837024009225/0001558370-24-009225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000155837024009225/apre-20240617x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer